



Combined Shareholders Meeting
Approval of all the resolutions and
Appointment of Thomas Hofstaetter as independent Board Member

Paris, May 31, 2012 – BioAlliance Pharma SA (Euronext Paris - BIO), a Company dedicated to orphan oncology products and specialty products, announces that its Shareholders' meeting was held today at its headquarters and has adopted all the resolutions supported by its Board of Directors.

Among other decisions, the Shareholders' meeting has appointed Thomas Hofstaetter as independent Board Member, increasing thus the number of independent members to 5 out of a total of 8.

With a Ph.D. Degree in Biochemistry and Molecular Biology, Thomas Hofstaetter has conducted an international career in Germany, in the United States and in Japan, within international groups (Wyeth, Aventis...) where he hold strategic positions at the highest level in external growth and business development. For the last two years and until December 2011, he has been CEO of VaxInnate Corporation and he is today board member of another American biotech company, Geron Corporation.

« We are delighted to have Thomas Hofstaetter joining our Board. His appointment is in line with the Board's ongoing strategy to involve international profiles. Thomas' experience and expertise in business/corporate development will be particularly important to support BioAlliance' future strategic initiatives», declares Judith Greciet, CEO of BioAlliance Pharma.

Besides, due to internal organization changes, ING Belgium, represented by Luc Van de Steen, has announced at the last Board meeting of BioAlliance Pharma its wish to resign from its Board member mandate.

"I wish to thank ING Belgium for its support and its confidence as BioAlliance' shareholder and Luc Van de Steen for his constant involvement in our Board", declares Patrick Langlois, Chairman of BioAlliance Board of Directors. *"I am happy to welcome Thomas Hofstaetter who, together with the other Board's members, will do his best to bring his expertise and his know-how to the Company in the objective of a strong growth".*

As of today, BioAlliance Pharma's Board of Directors is composed of:

- Patrick Langlois, Chairman of the Board of Directors and independent Board Member

- Judith Greciet, Chief Executive Officer and Board Member
- Michel Arié, independent Board Member
- Catherine Dunand, independent Board Member
- Thomas Hofstaetter, independent Board Member
- David H. Solomon, independent Board Member
- Financière de la Montagne, represented by Nicolas Trebouta, Board Member
- Kurma Life Sciences Partners, represented by Rémi Droller, Board Member

Voting results of the Combined Shareholders Meeting are available on our website at www.bioalliancepharma.com, section Investors/Shareholders' meeting.

About BioAlliance Pharma

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products

Loramyc[®]/Oravig[®] (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)

Sitavir[®]/Sitavig[®] (Acyclovir Lauriad[™]) (labialis herpes): Positive phase III final results; registration status

Fentanyl Lauriad[™] (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products

Livatag[®] (Doxorubicin Transdrug[™]) in primary liver cancer: Phase III on going

Validive[™] (clonidine Lauriad[™]) in mucositis: Phase II on going

AMEP[®] (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2011 Reference Document filed with the AMF on April 24, 2012, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Judith Greciet, CEO

Tel +33 1 45 58 76 00

judith.greciet@bioalliancepharma.com

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00

nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

caroline@alizerp.com